Prosonix Appoints Cécile Miles as Chief Business Officer
Complete the form below to unlock access to ALL audio articles.
Prosonix has appointed Cécile Miles as Chief Business Officer. In this newly created role, Ms Miles will help develop and drive Prosonix’ business development and commercial strategy, which is designed to capitalize on the potential value of its portfolio of directly substitutable generic and novel inhaled respiratory candidates.
Ms Miles has extensive business development and commercial experience within the pharmaceutical, biotechnology and generics sector, and strong global networks.
She joins Prosonix from the Watson group (now known as Actavis, Inc.), the world's third-largest generics company, where she was Commercial Director EU.
Before Watson, Ms Miles was Executive Director of Commercial Development at Ark Therapeutics, Executive Director of Global Business Development at Pliva, and Head of the European Division at Ranbaxy Laboratories Ltd. She also spent several years in a variety of commercial roles at Fisons plc.
Commenting on the appointment, David Hipkiss, Prosonix’ CEO, said: “Cécile is a highly experienced business development professional and brings excellent complementary skills and understanding of the generics and speciality pharmaceutical markets to Prosonix. She will play a key role in driving Prosonix’ business development strategy over the coming years as we explore opportunities to capture the full potential value of our portfolio of directly substitutable inhaled generics and novel combination respiratory candidates. 2013 is expected to be an exciting year as we prepare to submit our application for marketing approval with European regulators for PSX1001, to initiate first clinical trials of PSX1002, and to advance the development of our novel PSX2000 combination candidates to address a range of respiratory diseases.”
Cécile Miles added: “I am very excited to be joining the Prosonix team at this crucial juncture in the Company’s development. Prosonix is approaching some important development milestones in 2013 with the lead candidates in its respiratory medicine pipeline. In addition, the Company is receiving great interest from third parties about the potential of its platform both to develop new medicines and to optimize those that are currently used in the treatment of respiratory diseases.”
